GO:0050730 regulation of peptidyl-tyrosine phosphorylation: Signaling Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050730 describes any process that modulates the frequency, rate or extent of phosphorylation of peptidyl-tyrosine, a central post-translational modification in cell signaling.
• Dysregulation of peptidyl-tyrosine phosphorylation is linked to cancer, dementia, diabetic complications, and developmental disorders.
• Key regulators include protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), such as PTPN1, PTCH1, and others identified in omics studies.
• Bioinformatics and network pharmacology analyses frequently highlight this GO term as a hub in disease-associated pathways.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal testing of genes controlling peptidyl-tyrosine phosphorylation.
• Understanding this process aids biomarker discovery and therapeutic targeting in precision medicine.
Description
Regulation of peptidyl-tyrosine phosphorylation (GO:0050730) is a fundamental biological process that controls the addition of phosphate groups to tyrosine residues on proteins, a reversible modification critical for signal transduction, cell growth, differentiation, and metabolism. This process is orchestrated by the opposing activities of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), ensuring tight spatiotemporal control of signaling networks. Dysregulation of this balance is implicated in a wide range of human diseases, including cancer, neurodegenerative disorders, and metabolic conditions. Researchers study GO:0050730 to identify biomarkers, understand disease mechanisms, and develop targeted therapies. High-throughput omics and network pharmacology approaches have repeatedly identified this term as a central node in disease-associated pathways, underscoring its importance in biomedical research.
regulation of peptidyl-tyrosine phosphorylation At A Glance
| GO ID | GO:0050730 |
|---|---|
| GO term | regulation of peptidyl-tyrosine phosphorylation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the addition of phosphate groups to tyrosine residues on proteins, controlling signal transduction, cell proliferation, differentiation, and metabolism. |
| Key enzymes | Protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). |
| Associated diseases | Cancer, dementia, diabetic nephropathy, testicular developmental defects. |
| Research approaches | CRISPR knockout/knock-in, omics, network pharmacology, high-throughput screening. |
What Is GO:0050730?
GO:0050730, regulation of peptidyl-tyrosine phosphorylation, refers to any biological process that modulates the frequency, rate, or extent of the phosphorylation of peptidyl-tyrosine. In simpler terms, it covers all the mechanisms that control when and how much phosphate is added to tyrosine residues on proteins, a key switch in cellular communication.
Why Is regulation of peptidyl-tyrosine phosphorylation Important in Cell Biology?
Regulation of peptidyl-tyrosine phosphorylation is essential for normal cellular physiology and its disruption underlies numerous pathologies. It serves as a central hub integrating extracellular signals with intracellular responses, making it a prime target for therapeutic intervention and biomarker discovery.
• Controls cell growth, differentiation, and survival through reversible tyrosine phosphorylation.
• Dysregulation is a hallmark of many cancers, including bladder cancer and glioma.
• Implicated in neurodegenerative diseases such as dementia.
• Plays a role in metabolic disorders like diabetic nephropathy and nephrotic syndrome.
• Involved in testicular development and spermatogenesis.
• Key target for kinase inhibitor drugs and precision medicine.
• Frequently identified as a hub pathway in bioinformatics and network pharmacology studies.
• Enables high-throughput screening for modulators of signaling.
• Provides biomarkers for disease diagnosis and prognosis.
• Facilitates understanding of PTK/PTP balance in health and disease.
What Happens During regulation of peptidyl-tyrosine phosphorylation?
Initiation by Protein Tyrosine Kinases
In simple terms: Kinases add phosphate groups to tyrosine residues, starting the signal.
Protein tyrosine kinases (PTKs) catalyze the transfer of a phosphate group from ATP to the hydroxyl group of tyrosine residues on target proteins. This event is often triggered by receptor activation or intracellular signaling cues, leading to conformational changes and recruitment of downstream effectors. Dysregulated PTK activity is associated with oncogenesis and other diseases.
Opposing Action of Protein Tyrosine Phosphatases
In simple terms: Phosphatases remove phosphate groups, turning the signal off.
Protein tyrosine phosphatases (PTPs) counteract PTK activity by hydrolyzing the phosphate group from phosphotyrosine residues. This reversible regulation ensures signal termination and prevents sustained activation. PTPN1 (PTP1B) is a well-studied example involved in metabolic and developmental processes.
Integration with Signaling Networks
In simple terms: The phosphorylation status is fine-tuned by many interacting proteins.
Regulation of peptidyl-tyrosine phosphorylation is embedded in complex signaling networks. Scaffold proteins, adaptors, and feedback loops modulate the balance between kinases and phosphatases. Network pharmacology and bioinformatics analyses have highlighted this process as a central node in pathways related to cancer, diabetic nephropathy, and nephrotic syndrome.
Spatiotemporal Control
In simple terms: The process is controlled in time and space within the cell.
Subcellular localization of kinases and phosphatases, as well as their substrate specificity, ensures precise spatiotemporal regulation. Disruption of this control can lead to pathological conditions such as tumor progression and neurodegenerative disorders.
Role in Disease-Associated Pathways
In simple terms: When regulation fails, diseases can develop.
Altered peptidyl-tyrosine phosphorylation is linked to bladder cancer, glioma, breast cancer recurrence, and diabetic complications. Studies using high-throughput screening and omics have identified key regulators and potential therapeutic targets within this process.
Key Genes Involved in GO:0050730 regulation of peptidyl-tyrosine phosphorylation
The following genes and proteins are key players in the regulation of peptidyl-tyrosine phosphorylation, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTPN1 | Protein tyrosine phosphatase, negative regulator | Testicular development, spermatogenesis, metabolic regulation |
| PTCH1 | Receptor in Hedgehog signaling, influences tyrosine phosphorylation | Breast cancer recurrence prediction |
| PTPN11 | Protein tyrosine phosphatase, positive regulator of RAS signaling | Developmental disorders, cancer |
| EGFR | Receptor tyrosine kinase, phosphorylates tyrosine residues | Cancer biomarker and therapeutic target |
| SRC | Non-receptor tyrosine kinase, promotes phosphorylation | Oncogenesis, signal transduction |
| JAK2 | Tyrosine kinase, mediates cytokine signaling | Myeloproliferative neoplasms, inflammation |
| STAT3 | Transcription factor activated by tyrosine phosphorylation | Cancer, immune regulation |
| PTPRC | CD45, regulates immune cell signaling | Immune disorders, leukemia |
| INSR | Insulin receptor tyrosine kinase | Diabetes, metabolic syndrome |
| MET | Receptor tyrosine kinase | Cancer progression, metastasis |
| ALK | Receptor tyrosine kinase | Lymphoma, lung cancer |
| FGFR1 | Fibroblast growth factor receptor kinase | Developmental disorders, cancer |
| PDGFRB | Platelet-derived growth factor receptor kinase | Fibrosis, cancer |
| ABL1 | Non-receptor tyrosine kinase | Chronic myeloid leukemia |
| PTK2 | Focal adhesion kinase, regulates cell adhesion | Cancer invasion, metastasis |
| PTPN6 | SHP-1, negative regulator of immune signaling | Autoimmunity, lymphoma |
| CSK | C-terminal Src kinase, negative regulator | Cancer, immune regulation |
How Is regulation of peptidyl-tyrosine phosphorylation Regulated?
The regulation of peptidyl-tyrosine phosphorylation is itself controlled by multiple mechanisms, including feedback loops, protein-protein interactions, and subcellular localization. For example, PTPN1 activity can be modulated by oxidation, while kinases like SRC are regulated by phosphorylation and binding partners. Network pharmacology studies have shown that herbal formulations can modulate this process in diabetic nephropathy and nephrotic syndrome. Additionally, microRNAs such as miR-124-3p can regulate PTPN1 expression, impacting testicular development.
regulation of peptidyl-tyrosine phosphorylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTPN1 | Testicular developmental defects, metabolic disorders | Knockout mouse, spermatogenesis assays |
| PTCH1 | Breast cancer recurrence | Knock-in mutant breast cancer cell lines |
| EGFR | Bladder cancer, glioma | Overexpression and knockout in cancer cell lines |
| JAK2 | Diabetic nephropathy | Point mutation knock-in in renal cells |
| SRC | Cancer progression | CRISPR knockout in tumor models |
Cancer
Dysregulated peptidyl-tyrosine phosphorylation is a hallmark of many cancers. In bladder cancer, bioinformatics analyses identified key biomarkers related to this process. Glioma studies revealed differentially methylated genes involved in tyrosine phosphorylation. PTCH1 mutations predict breast cancer recurrence, highlighting the clinical relevance of this pathway.
Neurodegeneration and Dementia
Plasma proteomic biomarkers associated with poor cardiovascular health and incident dementia include proteins involved in tyrosine phosphorylation signaling, suggesting a role in neurodegenerative processes.
Metabolic and Renal Disorders
Diabetic nephropathy and nephrotic syndrome involve altered tyrosine phosphorylation. Network pharmacology analyses of traditional medicines have highlighted this process as a therapeutic target. Additionally, PTPN1 is implicated in testicular development and spermatogenesis, linking this process to reproductive disorders.
Wound Healing
High-throughput screening has identified natural polyphenol nano-vesicles that accelerate diabetic wound healing, potentially through modulation of tyrosine phosphorylation pathways.
From regulation of peptidyl-tyrosine phosphorylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PTPN1 affect spermatogenesis? | PTPN1 knockout mouse |
| Does mutant PTCH1 drive breast cancer recurrence? | PTCH1 point mutation knock-in |
| Can overexpression of EGFR enhance tumor growth? | EGFR overexpression cell line |
| What is the role of JAK2 in diabetic nephropathy? | JAK2 knock-in mutation in renal cells |
| Does SRC inhibition reduce metastasis? | SRC knockout in cancer cells |
| Can miR-124-3p regulate PTPN1 in testis? | miR-124-3p knockout/overexpression mouse |
How to Study the regulation of peptidyl-tyrosine phosphorylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphoproteomics | Global tyrosine phosphorylation levels | Biomarker discovery |
| Network pharmacology | Drug-target-pathway interactions | Mechanism of herbal medicines |
| High-throughput screening | Modulators of phosphorylation | Drug discovery |
| CRISPR knockout | Gene function loss | Causal gene validation |
| CRISPR knock-in | Specific mutations | Disease modeling |
| RNA-seq | Transcriptomic changes | Pathway analysis |
| Western blot | Specific protein phosphorylation | Validation of signaling |
Bioinformatics and Network Pharmacology
Bioinformatics analyses of transcriptomic and proteomic data identify key genes and pathways associated with peptidyl-tyrosine phosphorylation. Network pharmacology integrates drug-target interactions to predict therapeutic modulators.
High-Throughput Screening
High-throughput screening assays enable the discovery of small molecules or nanoparticles that modulate tyrosine phosphorylation, as demonstrated in diabetic wound healing studies.
CRISPR-Based Functional Genomics
CRISPR knockout, knock-in, and point mutation models allow causal testing of specific genes in the regulation of peptidyl-tyrosine phosphorylation.
Proteomics and Phosphoproteomics
Mass spectrometry-based phosphoproteomics quantifies changes in tyrosine phosphorylation across conditions, revealing signaling dynamics and biomarkers.
How CRISPR Can Be Used to Study GO:0050730 regulation of peptidyl-tyrosine phosphorylation
Knockout
CRISPR knockout of genes such as PTPN1 or SRC enables researchers to assess their necessity in regulating peptidyl-tyrosine phosphorylation. For example, PTPN1 knockout mice exhibit defects in spermatogenesis, confirming its role.
Point Mutation
Introducing point mutations in kinase or phosphatase genes, such as PTCH1, allows modeling of disease-associated variants and testing their impact on tyrosine phosphorylation and cancer recurrence.
Knock-in
Knock-in of tagged or mutant alleles, like JAK2 V617F, provides insights into how specific mutations alter signaling in diseases such as diabetic nephropathy.
Overexpression
Overexpression of EGFR or other tyrosine kinases in cell lines can mimic oncogenic signaling and is used to study tumor growth and drug resistance.
How EDITGENE Supports regulation of peptidyl-tyrosine phosphorylation Research
Researchers studying regulation of peptidyl-tyrosine phosphorylation-related genes often need to determine whether a candidate gene is causally involved in disease or normal physiology. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for regulation of peptidyl-tyrosine phosphorylation research.
Frequently Asked Questions About regulation of peptidyl-tyrosine phosphorylation
What is GO:0050730?
GO:0050730 is the Gene Ontology term for regulation of peptidyl-tyrosine phosphorylation, describing any process that modulates the addition of phosphate groups to tyrosine residues on proteins.
What genes are involved in regulation of peptidyl-tyrosine phosphorylation?
Key genes include PTPN1, PTCH1, EGFR, SRC, JAK2, and STAT3, among others.
How is peptidyl-tyrosine phosphorylation regulated?
It is regulated by the opposing activities of protein tyrosine kinases and phosphatases, as well as feedback loops and subcellular localization.
Why is regulation of peptidyl-tyrosine phosphorylation important in cancer?
Dysregulation leads to uncontrolled cell growth and survival, making it a target for cancer therapy and biomarker discovery.
What diseases are associated with GO:0050730?
Cancer, dementia, diabetic nephropathy, nephrotic syndrome, and testicular developmental defects.
How can CRISPR help study regulation of peptidyl-tyrosine phosphorylation?
CRISPR knockout, knock-in, and point mutation models allow causal testing of specific genes in this pathway.
What methods are used to study peptidyl-tyrosine phosphorylation?
Phosphoproteomics, network pharmacology, high-throughput screening, and CRISPR screens.
What is the role of PTPN1 in this process?
PTPN1 is a protein tyrosine phosphatase that negatively regulates tyrosine phosphorylation and is involved in testicular development and metabolism.
Can natural compounds modulate peptidyl-tyrosine phosphorylation?
Yes, network pharmacology studies show that herbal formulations can modulate this process in diabetic nephropathy and nephrotic syndrome.
How does EDITGENE support research on GO:0050730?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study this pathway.
Conclusion
Regulation of peptidyl-tyrosine phosphorylation (GO:0050730) is a central biological process controlling signal transduction, with profound implications for human health and disease. Understanding its mechanisms through CRISPR-based models and omics approaches can reveal novel therapeutic targets and biomarkers. EDITGENE provides the tools and expertise to accelerate this research.
References
- 1. Beydoun MA et al.. 2024. Plasma proteomic biomarkers and the association between poor cardiovascular health and incident dementia: The UK Biobank study.. Brain Behav Immun 119:995-1007 PMID: 38710337
- 2. Liu W et al.. 2023. Bioinformatics analysis of key biomarkers for bladder cancer.. Biomed Rep 18(2):14 PMID: 36643693
- 3. Xue J et al.. 2019. Identification of core differentially methylated genes in glioma.. Oncol Lett 18(6):6033-6045 PMID: 31788078
- 4. Luo L et al.. 2024. miR-124-3p regulates the involvement of Ptpn1 in testicular development and spermatogenesis in mouse.. Gene 893:147967 PMID: 37931856
- 5. Wang CY et al.. 2019. Mutation of the PTCH1 gene predicts recurrence of breast cancer.. Sci Rep 9(1):16359 PMID: 31704974
- 6. Chan KW et al.. 2022. Potential Therapeutic Targets of Rehmannia Formulations on Diabetic Nephropathy: A Comparative Network Pharmacology Analysis.. Front Pharmacol 13:794139 PMID: 35387335
- 7. Zhao X et al.. 2024. High-throughput screening-based design of multifunctional natural polyphenol nano-vesicles to accelerate diabetic wound healing.. J Nanobiotechnology 22(1):725 PMID: 39574119
- 8. Wang Y et al.. 2020. Evaluation of the mechanism of Danggui-Shaoyao-San in regulating the metabolome of nephrotic syndrome based on urinary metabonomics and bioinformatics approaches.. J Ethnopharmacol 261:113020 PMID: 32592886
